IMPACT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK IN PATIENTS TREATED WITH UPADACITINIB VERSUS COMPARATORS: POST HOC ANALYSIS OF THE SELECT RHEUMATOID ARTHRITIS PROGRAM

被引：0
|
作者：
Charles-Schoeman, C. [1 ]
Buch, M. H. [2 ,3 ]
Burmester, G. R. [4 ]
Liu, J. [5 ]
Dilley, D. [5 ]
Palac, H. [5 ]
Strengholt, S. [5 ]
Curtis, J. [6 ]
机构：
[1] Univ Calif Los Angeles, Div Rheumatol, Dept Med, Los Angeles, CA USA
[2] Univ Manchester, Manchester, Lancs, England
[3] NIHR Manchester Biomed Res Ctr, Ctr Musculoskeletal Res, Fac Biol Med & Hlth, Manchester, Lancs, England
[4] Charite Univ Med Berlin, Dept Rheumatol & Clin Immunol, Berlin, Germany
[5] AbbVie, Immunol, N Chicago, IL USA
[6] Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, Birmingham, AL USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
Safety; Targeted synthetic drugs; Cardiovascular disease;
D O I：
10.1136/annrheumdis-2023-eular.3337
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS0828
引用
收藏
页码：711 / 712
页数：2
相关论文
共 50 条
  • [1] Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme
    Fleischmann, Roy
    Curtis, Jeffrey R.
    Charles-Schoeman, Christina
    Mysler, Eduardo
    Yamaoka, Kunihiro
    Richez, Christophe
    Palac, Hannah
    Dilley, Deanne
    Liu, Jianzhong
    Strengholt, Sander
    Burmester, Gerd
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (09) : 1130 - 1141
  • [2] Characterization of Remission in Patients with Rheumatoid Arthritis Treated with Upadacitinib or Comparators
    Hall, Stephen
    Takeuchi, Tsutomu
    Thomson, Glen
    Emery, Paul
    Combe, Bernard
    Everding, Andrea
    Pavelka, Karel
    Song, Yanna
    Shaw, Tim
    Friedman, Alan
    Song, In-Ho
    Mysler, Eduardo
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [3] CHARACTERIZATION OF REMISSION IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH UPADACITINIB OR COMPARATORS
    Hall, Stephen
    Takeuchi, Tsutomu
    Thomson, Glen
    Emery, Paul
    Combe, Bernard
    Everding, Andrea
    Pavelka, Karel
    Song, Yanna
    Shaw, Tim
    Friedman, Alan
    Song, In-Ho
    Mysler, Eduardo
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 362 - 362
  • [4] CHARACTERISATION OF REMISSION IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH UPADACITINIB OR COMPARATORS
    Hall, Stephen
    Takeuchi, Tsutomu
    Thomson, Glen
    Emery, Paul
    Combe, Bernard
    Everding, Andrea
    Pavelka, Karel
    Song, Yanna
    Shaw, Tim
    Friedman, Alan
    Song, In-Ho
    Mysler, Eduardo
    RHEUMATOLOGY, 2020, 59 : 93 - 93
  • [5] Evaluating the efficacy of upadacitinib in patients with moderate rheumatoid arthritis: a post-hoc analysis of the SELECT phase 3 trials
    Conaghan, Philip G.
    Pavelka, Karel
    Hsieh, Song-Chou
    Bonnington, Terri-Leigh
    Kent, Toby C.
    Marchbank, Katie
    Edwards, Christopher J.
    RHEUMATOLOGY ADVANCES IN PRACTICE, 2022, 7 (01)
  • [6] Comparison of Composite Indices for Disease Activity in Patients with Psoriatic Arthritis Treated with Upadacitinib: A Post-Hoc Analysis from SELECT-PsA 1
    Smolen, Josef
    Lubrano, Ennio
    Kishimoto, Mitsumasa
    Balanescu, Andra R.
    Strand, Vibeke
    Gao, Tianming
    Vranich, Nancy
    Lippe, Ralph
    Tillett, William
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3790 - 3792
  • [7] Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE
    Mysler, Eduardo
    Tanaka, Yoshiya
    Kavanaugh, Arthur
    Aletaha, Daniel
    Taylor, Peter C.
    Song, In-Ho
    Shaw, Tim
    Song, Yanna
    DeMasi, Ryan
    Ali, Mira
    Fleischmann, Roy
    RHEUMATOLOGY, 2023, 62 (05) : 1804 - 1813
  • [8] COMPARISON OF COMPOSITE INDICES FOR DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH UPADACITINIB: A POST-HOC ANALYSIS FROM SELECT-PSA 1
    Smolen, J. S.
    Lubrano, E.
    Kishimoto, M.
    Balanescu, A.
    Strand, V.
    Gao, T.
    Vranich, N.
    Lippe, R.
    Tillett, W.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 824 - 824
  • [9] Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
    Charles-Schoeman, Christina
    Buch, Maya H.
    Dougados, Maxime
    Bhatt, Deepak L.
    Giles, Jon T.
    Ytterberg, Steven R.
    Koch, Gary G.
    Vranic, Ivana
    Wu, Joseph
    Wang, Cunshan
    Kwok, Kenneth
    Menon, Sujatha
    Rivas, Jose L.
    Yndestad, Arne
    Connell, Carol A.
    Szekanecz, Zoltan
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (01) : 119 - 129
  • [10] Cardiovascular Risk in Rheumatoid Arthritis Patients Treated with Methotrexate versus Hydroxychloroquine
    He, Mengdong
    Pawar, Ajinkya
    Desai, Rishi
    Glynn, Robert
    Lee, Hemin
    Weinblatt, Michael
    Solomon, Daniel H.
    Kim, Seoyoung
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
12345